Outcome of a second-line protease inhibitor - Containing regimen in patients failing or intolerant of a first highly active antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 24, Issue 2, 2000, Pages 115-122

  Bini, Teresa ^a   Testa, Letizia ^a   Chiesa, Elisabetta ^a   Adorni, Fulvio ^b   Abeli, Clara ^a   Castelnuovo, Barbara ^a   Melzi, Sara ^a   Sollima, Salvatore ^a   Bongiovanni, Marco ^a   D'Arminio Monforte, Antonella ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b CNR   (Italy)

Author keywords

Intolerance toxicity; Protease inhibitors; Second line regimens; Virologic failure

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGING; ARTICLE; DRUG HYPERSENSITIVITY; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS ISOLATION; VIRUS RESISTANCE;

EID: 12944251048     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-200006010-00005     Document Type: Article

References (29)

1. Palella FJ, Kathleen M, Delaney KM, et al. and the HIV Outpatients Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
2. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
3. Li TS, Tubiana R, Katlama C, Calvez C, Ait Mohand H, Autran B. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998;351:1682-6.
4. Fatkenheuer G, Theisen A, Rockstroh J, et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997;11:F113-6.
5. Ledergerber B, Egger M, Opravil M, et al. for the Swiss HIV Cohort Study. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-I patients: a prospective cohort study. Lancet 1999;353:863-8.
6. Friedland GH, Williams A. Attaining higher goals in HIV treatment: the central importance of adherence. AIDS 1999;13(Suppl 1):S61-72.
7. Hirsch MS, Conway B, D'Aquila RT, et al. for the International AIDS Society-USA Panel. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. JAMA 1998;279:1984-91.
8. Clough LA, D'Agata E, Raffanti S, Haas DW. Factors that predict incomplete virological response to protease inhibitor-based antiretroviral therapy. Clin Infect Dis 1999;29:75-81.
9. + cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999;13: F35-43.
10. Boden D, Markowitz M. Resistance to HIV-1 protease inhibitors. Antimicrob Agents Chemother 1998;42:2775-83.
11. Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992;41:19-23.
12. Dronda F, Casado JL, Perez-Elias MJ, et al. Response to indinavir in HIV-infected patients failing to respond to saquinavir therapy: importance of HIV viral load [abstract 12306]. Presented at the XII World Conference on AIDS, Geneva, 1998.
13. Poggi CI, Lafeuillade A, Hittinger G, et al. Limited efficacy of nelfinavir after failure of other protease inhibitors (PI) [abstract 12281]. Presented at the XII World Conference on AIDS, Geneva, 1998.
14. Tebas P, Patick AK, Kane EM, et al. Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir. AIDS 1999;13:F23-8.
15. d'Arminio Monforte A, Lepri AC, Rezza G, et al. Insights into the reasons for discontinutaiton of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients: ICONA Study Group. AIDS 2000;14(5):499-507.
16. Guardiola J, Domingo P, Madrid F, et al. Protease inhibitor (PI) change within a triple anti-retroviral therapy in HIV-AIDS infected patients [abstract 60321]. Presented at the XII World Conference on AIDS, Geneva, 1998.
17. d'Arminio Monforte A, Testa L, Adorni F, et al. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-I infection. AIDS 1998:12:1631-37.
18. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Washington, DC: U.S. Department of Health and Human Services, May 1999.
19. Gazzard B, Moyle G, on behalf of the BHIVA Guidelines Writing Committee. 1998 Revision to the British HIV association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1998;352:314-6.
20. Bernasconi E, Magenta L, Piffaretti JC, et al. Are nelfinavir-containing regimens effective as second-line triple therapy [abstract 22381]. Presented at the XII World Conference on AIDS, Geneva, 1998.
21. Hall CS, Raines CP, Bamett SH, Moore RD, Gallant JE. Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens. AIDS 1999;13: 1207-12.
22. Decks SG, Grant MR, Beany GW, Horton C, Detmer J, Eastman S. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure. AIDS 1998;12:F97-102.
23. Piketty C, Castiel P, Belec L, et al. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS 1998;12:745-50.
24. Kaufmann D, Pantaleo G, Sudre P, Telenti A, for the Swiss HIV Cohort Study. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Lancet 1998;351:423-4.
25. d'Arminio Monforte A, Testori V, Adorni F, et al. CD4 cell counts at the third month of HAART may predict clinical failure. AIDS 1999;13:1669-76.
26. Noble S, Faulds D. Saquinavir: a review of its pharmacology and clinical potential in the management of HIV infection. Drugs 1996; 52:93-112.
27. Lawrence J, Schapiro J, Winters M, et al. Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons. J Infect Dis 1999;179:1356-64.
28. Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotype in HIV therapy: the VIRADAPT randomized controlled trial. Lancet 1999;353:2195-9.
29. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Merigan TC, and the CPCRA 046 Study Team. A pilot study of the short-term effects of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy [abstract LB8]. Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999.